Annegret Van der Aa, PhD

CSO & CDO

Annegret Van der Aa, PhD has a broad R&D experience in small and mid-size biotech (Innogenetics, ActoGeniX, OCTIMET Oncology, and Galapagos) for nearly 20 years.

Annegret is an immunologist by training with a PhD obtained at Hasselt University.

Subsequently, she took up increasing responsibilities in various R&D positions covering the full spectrum from research to up late clinical development. This included managing a research group, compound strategic and operational leadership to building a clinical development/operations department which resulted in the transitioning of more than 10 preclinical candidates to clinical stage products.

Moreover, Annegret has deep scientific and operational expertise and built a broad network over the past 20 years in the field of auto-immune and chronic inflammatory diseases.

At Galapagos, she has been instrumental in the clinical development of Jyseleca® (filgotinib), which was approved for a first indication in 2020.

Management team

Scientific Advisor

Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris

Board Of Directors​

Scientific Advisory Board

Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris
Chief Executive Officer of the Institute for Research in Immunology and Cancer at the University of Montréal
Professor of Target and Systems Biochemistry at the Faculty of Science of the Vrije Universiteit Amsterdam
Gardiner Professor of Biochemistry, and Deputy Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow